BioSpace News Archive

The Society for Clinical Research Sites (SCRS) announced today that StudyKIK has joined the organization as a Global Impact Partner (GIP)

Enable Injections, Inc., a company developing and manufacturing advanced wearable infusion devices for combination products, today announced it has entered into a multi-product development agreement with Sanofi S.A

Bristol-Myers Squibb Company (NYSE: BMY) today announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.

Berkshire Health Systems, Jackson Health System, John Peter Smith Hospital, Liberty Hospital and University of Kansas Health System Select PartsSource Pro to Achieve Best-in-Class Clinical Engineering Outcomes

Abzena, the leading biotherapeutics target to GMP partner research organization (PRO) announced an accelerated program to IND. This reduces timeline from stable pool to GMP down to 14 months.

Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), will present its ASCO Direct™ Highlights on Saturday, June 29 at the Embassy Suites by Hilton Charlotte Uptown in Charlotte, North Carolina.

Young Innovations, a leading global supplier of dental products, announced the acquisition of Germiphene Corporation.

Brooklyn ImmunoTherapeutics announced the presentation of an ongoing trial poster at the 2019 American Society of Clinical Oncology Annual Meeting on May 31 - June 4, 2019 at the McCormick Place in Chicago, IL.

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada), today presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with germline BRCA1/2-mutated (gBRCAm) advanced ovarian cancer, who have received two more prior lines of chemotherapy

Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 230,500 shares of common stock to be distributed among 12 new employees, with a grant date of June 3, 2019.